small molecule glp 1 agonist PDB-101: of the Month: GLP-1 Receptor Agonists Synthetic small molecule GLP-1 secretagogues
Description
G.et al
GLP-1RAs like Semaglutide cause many adverse effects
With continued advertising and public awareness, this number could surpass 3,000 before 2026
Countries like China and India are experiencing a surge in demand for diabetes management solutions, supported by government initiatives aimed at improving healthcare infrastructure
Treatment with GLP-1RA downregulates NF-B activation in hepatic tissue, thereby leading to decreased transcription of cytokines and chemokines that sustain inflammation (23, 24)
In addition, people taking semaglutide in PIONEER-6 had a moderate reduction in cholesterol levels
